The success of GLP-1 receptor agonists and SGLT2 inhibitors, which we have discussed from a mechanistic angle, translates to clinical practice as well—these agents are now proven to reduce cardiovascular and renal events in T2D beyond glycemic control [276,277]. This evidence concerns the gene GLP1R and type 2 diabetes mellitus.